Abstract:Liver X receptors (LXRs) have been recognized as a promising therapeutic target for atherosclerosis; however, their role in insulin sensitivity is controversial. Adiponectin plays a unique role in maintaining insulin sensitivity. Currently, no systematic experiments elucidating the role of LXR activation in insulin function based on adiponectin signaling have been reported. Here, we investigated the role of LXR activation in insulin resistance based on adiponectin signaling, and possible mechanisms. C57BL/6 mice maintained on a regular chow received the LXR agonist, T0901317 (30 mg/kg.d) for 3 weeks by intraperitoneal injection, and differentiated 3T3-L1 adipocytes were treated with T0901317 or GW3965. T0901317 treatment induced significant insulin resistance in C57BL/6 mice. It decreased adiponectin gene transcription in epididymal fat, as well as serum adiponectin levels. Activity of AMPK, a key mediator of adiponectin signaling, was also decreased, resulting in decreased Glut-4 membrane translocation in epididymal fat. In contrast, adiponectin activity was not changed in the liver of T0901317 treated mice. In vitro, both T0901317 and GW3965 decreased adiponectin expression in adipocytes in a dose-dependent manner, an effect which was diminished by LXR alpha silencing. ChIP-qPCR studies demonstrated that T0901317 decreased the binding of PPAR gamma to the PPAR-responsive element (PPRE) of the adiponectin promoter in a dose-dependent manner. Furthermore, T0901317 exerted an antagonistic effect on the expression of adiponectin in adipocytes co-treated with 3 mu M Pioglitazone. In luciferase reporter gene assays, T0901317 dose-dependently inhibited PPRE-Luc activity in HEK293 cells co-transfected with LXR alpha and PPAR gamma. These results suggest that LXR activation induces insulin resistance with decreased adiponectin signaling in epididymal fat, probably due to negative regulation of PPAR gamma signaling. These findings indicate that the potential of LXR activation as a therapeutic target for atherosclerosis may be limited by the possibility of exacerbating insulin resistance-related disease.

[Research progress in regulation of adiponectin receptors expression].

Effect of adiponectin on obesity-linked diseases

Recent Advances on Adiponectin Receptor

Research progress of adiponectin and its receptors

Progress in Adiponectin

Mechanism of Action and Risk Prediction of Adiponectin in Cardiovascular Diseases

New advances of adiponectin in regulating obesity and related metabolic syndromes

Research progress of adipokines related with obesity

Transcription and post-translational mechanisms: dual regulation of adiponectin-mediated Occludin expression in diabetes

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

[Research progress in the regulation of functional homeostasis of adipose tissue by exosomal miRNA]

The Function of Adiponectin in the Initiation and Progression of Coronary Heart Disease

[Effect of AMP-activated Protein Kinase on Cardiovascular Protection of Adiponectin].

Overexpression of Adiponectin Receptors Potentiates the Antiinflammatory Action of Subeffective Dose of Globular Adiponectin in Vascular Endothelial Cells.

Research progresses on the role of adiponectin and its receptors in prostate cancer

Progress in Research of Adipokines and Insulin Resistance

Adiponectin and Adiponectin Receptors in Atherosclerosis

Role of Adiponectin in Cardiovascular Diseases Related to Glucose and Lipid Metabolism Disorders

Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives

Advances in Research of Association Between Adiponectin and Coronary Atherosclerosis

Effects of C-Reactive Protein on Adipokines Genes Expression in 3T3-L1 Adipocytes